Randomised, open-label, three-way crossover study investigating the bioavailability of methotrexate administered via a Medi-Jet Auto-injector or orally in adults with rheumatoid arthritis

Trial Profile

Randomised, open-label, three-way crossover study investigating the bioavailability of methotrexate administered via a Medi-Jet Auto-injector or orally in adults with rheumatoid arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Methotrexate (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Antares Pharma
  • Most Recent Events

    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 16 Oct 2013 Results will be presented at the 2013 American College of Rheumatology (ACR) Annual Meeting, according to an Antares Pharma media release.
    • 24 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top